GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
GENEDX HOLDINGS (WGS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does GENEDX HOLDINGS (WGS) Have the Potential to Rally 26.17% as Wall Street Analysts Expect?
The mean of analysts' price targets for GENEDX HOLDINGS (WGS) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GeneDx: Strong Testing Volume And An Invaluable Genomic Database
GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights over traditional panel testing. The company achieved a significant turnaround, becoming cash flow positive in Q4 2024 and Q1 2025 after years of net losses. Strategic restructuring, including shutting down Sema4's reproductive health unit, streamlined costs and sharpened focus on WGS's core strengths.
GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last?
GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know
The consensus price target hints at a 32.6% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GeneDx: Strong Fundamentals Intact As Market Misreads Test Volume Dip
GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance despite a minor sequential test volume dip. The volume decline is attributable to seasonality, adverse weather, and one fewer business day, not a structural slowdown; fundamentals remain robust. Strong pricing power and rising reimbursement rates drive revenue growth, setting a solid foundation for future acceleration as volumes rebound.
GeneDx: Time To Buy The Dip
GeneDx's recent 50% stock drop post-Q1 earnings is seen as an overreaction, despite a projected modest growth slowdown from 42% to 30-35%. The company is expanding product lines, improving margins, and increasing insurance coverage, with the recent acquisition of Fabric Genomics offering growth and cost synergies. GeneDx's valuation is attractive compared to peers, with a forward P/E of 30 and projected profitability next year, unlike Natera and Tempus AI.
GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.33 per share a year ago.
GENEDX HOLDINGS (WGS) Upgraded to Buy: Here's Why
GENEDX HOLDINGS (WGS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GeneDx: Strengthening Leadership In Genomic Diagnostics
GeneDx Holdings Corp. leverages genomic sequencing and data science for early diagnosis and treatment, focusing on pediatric outpatient and neonatal ICU settings. GeneDx will report Q1 2025 earnings on April 30, with expectations for continued revenue growth and margin improvement. Expanding market opportunity by leveraging data set expertise across more disease applications, new patient access channels, adult diagnostics, and international markets.
Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results?
GeneDx is expected to have continued the strong 2024 momentum across all metrics in the first quarter of 2025.
GeneDx Holdings: There Is Upside Potential, But Price Tag Is Rich
GeneDx Holdings Corp. is delivering strong revenue growth, but it is still burning cash, which makes me hesitant. At 7x sales, WGS stock feels expensive, given its current financials. If GeneDx can prove it can generate sustainable free cash flow, I'd reconsider my stance.
